CD274 and small cell lung carcinoma: Based on the abovementioned findings, the Food and Drug Administration (FDA) approved PD-L1 inhibitors, including atezolizumab and durvalumab, in combination with chemotherapy as the first-line regimen for treatment-naive patients with ES-SCLC in 2019 and 2020, respectively.